Shots:

• The P- IIIb ATLAS-2M study involves assessing long-acting cabotegravir and rilpivirine regimen for the treatment of HIV
• The ATLAS-2M 96wks. data reinforce the 1EPs @48wks. demonstrated the efficacy of every 2mos. dosing (q8w) was non-inferior to monthly dosing (q4w) dosing with (2.1% & 1.1%) participants having HIV-1 RNA ≥50 c/mL. The 2EPs @96 wks. showed virologic suppression were similar between the two arms with (91.0% & 90.2%) participants having RNA <50 c/mL- CVFs (1.7% & 0.4%) respectively
• The 2mos. dosing regimen of cabotegravir and rilpivirine is under investigation and not approved in the US or Canada

 ­ Ref: GSK | Image: ViiV Healthcare